Recommended

Subscribers

Sign in now to see personalised content appear here.

You can also see your reading history and subscription details on your subscriber page.

Why subscribe?
Find out more.

Sign up for your FREE email newsletter  +

New

Abzena signs new ThioBridge licence agreement

January 23, 2017

San Diego-based biopharmaceutical company licensed for antibody drug conjugate linker technolog ...

Ingredients | Europe | Manufacturing and Equipment

Prima BioMed announces new product candidate IMP761: a LAG-3 agonist antibody

January 9, 2017

Prima BioMed announces that it has developed a new early stage product candidate, a humanised I ...

Ingredients | R and D

The future of uniquely delivered drugs and ADCs

December 5, 2016

Kruthika Dhar of Thatís Nice reports on unique delivery drugs and the marketplace

Ingredients | R and D

Tiziana Life Sciences in-licenses NI-1201, a fully human anti-IL-6R monoclonal antibody

January 3, 2017

Exclusive worldwide license expands therapeutic pipeline in key immunological areas

Ingredients | R and D | Finance

Abzena signs licence agreement with Trieza

December 22, 2016

Licence agreement for Composite Human Antibody technology

Ingredients | North America | Finance

DuPont Industrial Biosciences to begin new research aimed to enable global access for Protein Medications

December 16, 2016

Gates Foundation Grant to address market need for high volume, affordable and rapid cycle time ...

Ingredients | R and D | Finance

GeNeuro and Servier announce ANGEL-MS extension clinical study in multiple sclerosis

December 7, 2016

ANGEL-MS extension study will offer the 260 patients enrolled in the on-going Phase IIb CHANGE- ...

Ingredients | Regulatory | R and D

Kymab new therapeutic antibody for autoimmune diseases shows potential for improvement in post-transplant survival

December 5, 2016

Leading monoclonal antibody biopharmaceutical group Kymab announces remarkable early stage resu ...

Ingredients | R and D